Selected research
Industry Research
Gemcitabine Industry Research Report 2026
Market perspective
The global Gemcitabine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Gemcitabine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Gemcitabine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Gemcitabine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Gemcitabine include Hisun Pharma, Pude Pharma, Qilu Pharma, Novartis, Mylan, Jari Pharma, Hansoh Pharma, Yibantian Pharma and HPGC, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Gemcitabine market in terms of revenue (US$ million) and, where applicable, sales volume (kg), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/kg) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Gemcitabine Market by Company
Hisun Pharma
Pude Pharma
Qilu Pharma
Novartis
Mylan
Jari Pharma
Hansoh Pharma
Yibantian Pharma
HPGC
Salius Pharma
Lilly France
Actavis
Accord Healthcare
Gemcitabine Segment by Type
1g/Vial
200mg/Vial
Gemcitabine Segment by Application
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Gemcitabine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gemcitabine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gemcitabine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gemcitabine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Gemcitabine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Gemcitabine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Gemcitabine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 1g/Vial
- 200mg/Vial
Applications
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Companies covered
- Hisun Pharma
- Pude Pharma
- Qilu Pharma
- Novartis
- Mylan
- Jari Pharma
- Hansoh Pharma
- Yibantian Pharma
- HPGC
- Salius Pharma
- Lilly France
- Actavis
- Accord Healthcare
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Gemcitabine Market Size (2021-2032)
- 2.2.2 Global Gemcitabine Sales (2021-2032)
- 2.2.3 Global Gemcitabine Market Average Price (2021-2032)
- 2.3 Gemcitabine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 1g/Vial
- 2.3.3 200mg/Vial
- 2.4 Gemcitabine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital Pharmacies
- 2.4.3 Online Pharmacies
- 2.4.4 Retail Pharmacies
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Gemcitabine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Gemcitabine Sales (kg) of Manufacturers (2021-2026)
- 3.3 Global Gemcitabine Revenue of Manufacturers (2021-2026)
- 3.4 Global Gemcitabine Average Price by Manufacturers (2021-2026)
- 3.5 Global Gemcitabine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Gemcitabine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Gemcitabine, Product Type & Application
- 3.8 Global Manufacturers of Gemcitabine, Established Date
- 3.9 Global Gemcitabine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Hisun Pharma
- 4.1.1 Hisun Pharma Company Information
- 4.1.2 Hisun Pharma Business Overview
- 4.1.3 Hisun Pharma Gemcitabine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Hisun Pharma Gemcitabine Product Portfolio
- 4.1.5 Hisun Pharma Recent Developments
- 4.2 Pude Pharma
- 4.2.1 Pude Pharma Company Information
- 4.2.2 Pude Pharma Business Overview
- 4.2.3 Pude Pharma Gemcitabine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Pude Pharma Gemcitabine Product Portfolio
- 4.2.5 Pude Pharma Recent Developments
- 4.3 Qilu Pharma
- 4.3.1 Qilu Pharma Company Information
- 4.3.2 Qilu Pharma Business Overview
- 4.3.3 Qilu Pharma Gemcitabine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Qilu Pharma Gemcitabine Product Portfolio
- 4.3.5 Qilu Pharma Recent Developments
- 4.4 Novartis
- 4.4.1 Novartis Company Information
- 4.4.2 Novartis Business Overview
- 4.4.3 Novartis Gemcitabine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Novartis Gemcitabine Product Portfolio
- 4.4.5 Novartis Recent Developments
- 4.5 Mylan
- 4.5.1 Mylan Company Information
- 4.5.2 Mylan Business Overview
- 4.5.3 Mylan Gemcitabine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Mylan Gemcitabine Product Portfolio
- 4.5.5 Mylan Recent Developments
- 4.6 Jari Pharma
- 4.6.1 Jari Pharma Company Information
- 4.6.2 Jari Pharma Business Overview
- 4.6.3 Jari Pharma Gemcitabine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Jari Pharma Gemcitabine Product Portfolio
- 4.6.5 Jari Pharma Recent Developments
- 4.7 Hansoh Pharma
- 4.7.1 Hansoh Pharma Company Information
- 4.7.2 Hansoh Pharma Business Overview
- 4.7.3 Hansoh Pharma Gemcitabine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Hansoh Pharma Gemcitabine Product Portfolio
- 4.7.5 Hansoh Pharma Recent Developments
- 4.8 Yibantian Pharma
- 4.8.1 Yibantian Pharma Company Information
- 4.8.2 Yibantian Pharma Business Overview
- 4.8.3 Yibantian Pharma Gemcitabine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Yibantian Pharma Gemcitabine Product Portfolio
- 4.8.5 Yibantian Pharma Recent Developments
- 4.9 HPGC
- 4.9.1 HPGC Company Information
- 4.9.2 HPGC Business Overview
- 4.9.3 HPGC Gemcitabine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 HPGC Gemcitabine Product Portfolio
- 4.9.5 HPGC Recent Developments
- 4.10 Salius Pharma
- 4.10.1 Salius Pharma Company Information
- 4.10.2 Salius Pharma Business Overview
- 4.10.3 Salius Pharma Gemcitabine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Salius Pharma Gemcitabine Product Portfolio
- 4.10.5 Salius Pharma Recent Developments
- 4.11 Lilly France
- 4.11.1 Lilly France Company Information
- 4.11.2 Lilly France Business Overview
- 4.11.3 Lilly France Gemcitabine Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Lilly France Gemcitabine Product Portfolio
- 4.11.5 Lilly France Recent Developments
- 4.12 Actavis
- 4.12.1 Actavis Company Information
- 4.12.2 Actavis Business Overview
- 4.12.3 Actavis Gemcitabine Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Actavis Gemcitabine Product Portfolio
- 4.12.5 Actavis Recent Developments
- 4.13 Accord Healthcare
- 4.13.1 Accord Healthcare Company Information
- 4.13.2 Accord Healthcare Business Overview
- 4.13.3 Accord Healthcare Gemcitabine Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Accord Healthcare Gemcitabine Product Portfolio
- 4.13.5 Accord Healthcare Recent Developments
5 Global Gemcitabine Market Scenario by Region
- 5.1 Global Gemcitabine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Gemcitabine Sales by Region: 2021-2032
- 5.2.1 Global Gemcitabine Sales by Region: 2021-2026
- 5.2.2 Global Gemcitabine Sales by Region: 2027-2032
- 5.3 Global Gemcitabine Revenue by Region: 2021-2032
- 5.3.1 Global Gemcitabine Revenue by Region: 2021-2026
- 5.3.2 Global Gemcitabine Revenue by Region: 2027-2032
- 5.4 North America Gemcitabine Market Facts & Figures by Country
- 5.4.1 North America Gemcitabine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Gemcitabine Sales by Country (2021-2032)
- 5.4.3 North America Gemcitabine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Gemcitabine Market Facts & Figures by Country
- 5.5.1 Europe Gemcitabine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Gemcitabine Sales by Country (2021-2032)
- 5.5.3 Europe Gemcitabine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Gemcitabine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Gemcitabine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Gemcitabine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Gemcitabine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Gemcitabine Market Facts & Figures by Country
- 5.7.1 South America Gemcitabine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Gemcitabine Sales by Country (2021-2032)
- 5.7.3 South America Gemcitabine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Gemcitabine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Gemcitabine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Gemcitabine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Gemcitabine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Gemcitabine Sales by Type (2021-2032)
- 6.1.1 Global Gemcitabine Sales by Type (2021-2032) & (kg)
- 6.1.2 Global Gemcitabine Sales Market Share by Type (2021-2032)
- 6.2 Global Gemcitabine Revenue by Type (2021-2032)
- 6.2.1 Global Gemcitabine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Gemcitabine Revenue Market Share by Type (2021-2032)
- 6.3 Global Gemcitabine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Gemcitabine Sales by Application (2021-2032)
- 7.1.1 Global Gemcitabine Sales by Application (2021-2032) & (kg)
- 7.1.2 Global Gemcitabine Sales Market Share by Application (2021-2032)
- 7.2 Global Gemcitabine Revenue by Application (2021-2032)
- 7.2.1 Global Gemcitabine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Gemcitabine Revenue Market Share by Application (2021-2032)
- 7.3 Global Gemcitabine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Gemcitabine Value Chain Analysis
- 8.1.1 Gemcitabine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Gemcitabine Production Mode & Process
- 8.2 Gemcitabine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Gemcitabine Distributors
- 8.2.3 Gemcitabine Customers
9 Global Gemcitabine Analyzing Market Dynamics
- 9.1 Gemcitabine Industry Trends
- 9.2 Gemcitabine Industry Drivers
- 9.3 Gemcitabine Industry Opportunities and Challenges
- 9.4 Gemcitabine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst